Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nabriva Therapeutics (DE:NTY)
FRANKFURT:NTY
Nabriva Therapeutics (NTY) Stock Price & Analysis
0 Followers
NTY Stock Chart & Stats
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Nov 09, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Nabriva Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.85% Other Institutional Investors
99.15% Public Companies and
Individual Investors
NTY FAQ
What was Nabriva Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Nabriva Therapeutics’s market cap?
Currently, no data Available
When is Nabriva Therapeutics’s upcoming earnings report date?
Nabriva Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is 181 days ago.
How were Nabriva Therapeutics’s earnings last quarter?
Currently, no data Available
Is Nabriva Therapeutics overvalued?
According to Wall Street analysts Nabriva Therapeutics’s price is currently same.
Does Nabriva Therapeutics pay dividends?
Nabriva Therapeutics does not currently pay dividends.
What is Nabriva Therapeutics’s EPS estimate?
Nabriva Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nabriva Therapeutics have?
Currently, no data Available
What happened to Nabriva Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nabriva Therapeutics?
Among the largest hedge funds holding Nabriva Therapeutics’s share is Aisling Capital Management LP. It holds Nabriva Therapeutics’s shares valued at 16K.
---
Nabriva Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.31%
12-Months-Change
Fundamentals
Return on Equity
-268.53%
Trailing 12-Months
Asset Growth
-63.00%
Trailing 12-Months
Company Description
Nabriva Therapeutics
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
---
NTY Stock 12 Month Forecast
Average Price Target
―Nabriva Therapeutics
―
Bio-Path Holdings
―
Akari Therapeutics
―
Agile Therapeutics
―
Trevena
―
Best Analysts Covering NTY
1 Year
1 Year Success Rate
1/19 ratings generated profit
1 Year Average Return
-67.48%
downgraded a sell rating a year ago
Copying Carl Byrnes's trades and holding each position for 1 Year would result in 5.26% of your transactions generating a profit, with an average return of -67.48% per trade.
---